论文部分内容阅读
目的:检测Aurora B激酶在原发性上皮性卵巢癌组织中的表达情况,探讨其在卵巢癌发生发展中的意义。方法:用免疫组织化学PV二步法测定Aurora B蛋白在卵巢癌(n=61)、良性卵巢肿瘤(n=20)及正常卵巢(n=15)组织中的表达。并对所有卵巢癌患者进行随访,探讨Aurora B表达水平的临床意义。结果:原发性上皮性卵巢癌组织中Aurora-B蛋白阳性表达率(77.05%)显著高于良性卵巢肿瘤组织(25.00%)及正常卵巢组织(6.67%)(P=0.000)。Aurora-B蛋白表达水平与临床手术分期及病理分级有关(P=0.000,P=0.017),而与组织类型及有无淋巴结转移无关(P=0.978,P=0.795)。单变量分析结果显示,Aurora-B与原发性上皮性卵巢癌复发有关。多变量分析结果显示,Aurora-B是影响患者复发的独立因素(P=0.000)。结论:Aurora-B蛋白的过度表达与上皮性卵巢癌的预后有关,有望成为观察患者预后的指标之一。
OBJECTIVE: To detect the expression of Aurora B kinase in primary epithelial ovarian cancer and to explore its significance in the development of ovarian cancer. Methods: The expression of Aurora B protein in ovarian cancer (n = 61), benign ovarian tumor (n = 20) and normal ovary (n = 15) tissues was determined by immunohistochemical PV two-step method. All patients with ovarian cancer were followed up to investigate the clinical significance of Aurora B expression. Results: The positive rate of Aurora-B protein in primary epithelial ovarian cancer (77.05%) was significantly higher than that in benign ovarian tumor (25.00%) and normal ovarian tissue (6.67%) (P = 0.000). Aurora-B protein expression was correlated with clinical stage and pathological grade (P = 0.000, P = 0.017), but not with tissue type and lymph node metastasis (P = 0.978, P = 0.795). Univariate analysis showed that Aurora-B was associated with the recurrence of primary epithelial ovarian cancer. Multivariate analysis showed that Aurora-B was an independent factor affecting the relapse (P = 0.000). Conclusion: Aurora-B protein overexpression is associated with the prognosis of epithelial ovarian cancer and is expected to become one of the prognostic indicators.